Loading asset research
Q3 2026 earnings · Nov 9
Zentalis Pharmaceuticals Inc. Common Stock
ZNTLNasdaq · USD · StocksQuote as of · Exchange session not verified$2.70
-5.92%
Today
ZNTL
Loading 1D prices…
Market cap
$260.3M
Volume
1.2M
52w high
$6.9552w low
$1.21Company profile
Zentalis Pharmaceuticals Inc. Common Stock
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
San Diego, CA, United States
Employees
106
Fiscal year end
1231
CIK
1725160
Session & valuation
Open$2.75
Previous close$2.75
Day high$2.77
Day low$2.65
30-day avg. volume1.1M
Outstanding shares71.7M
Diluted EPS-$1.91
Latest annual period
P/E (trailing)-1.41
P/E (forward)-1.52
Price / book1.37
Beta1.86
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| BCYCBicycle Therapeutics plc American Depositary Shares | $258.3M | $72.6M | -301.66% | -$3.16 | +3.61% | Buy |
| ACIUAC Immune SA Common Stock | $264.5M | — | — | -$0.70 | -6.01% | Buy |
| GLSIGreenwich LifeSciences Inc. Common Stock | $265.7M | $0.00 | — | -$1.43 | +3.37% | Buy |
| AKBAAkebia Therapeutics Inc. Common Stock | $254.4M | $236.2M | -2.24% | -$0.02 | -3.95% | Buy |
| LYELLyell Immunopharma Inc. Common Stock | $248M | $36K | -762355.56% | -$16.06 | -3.89% | Buy |